Trade

Transgene Biotek share price

High risk
  • 58%Low risk
  • 58%Moderate risk
  • 58%Balanced risk
  • 58%High risk
  • 58%Extreme risk
  • 2.99(9.93%)
    December 12, 2025 15:28:58 PM IST
    • NSE
    • BSE
  • Vol : 79.75 K (NSE + BSE)
    Last 20 day avg : 57.17 K

Transgene Biotek is trading 9.93% upper at Rs 2.99 as compared to its last closing price. Transgene Biotek has been trading in the price range of 2.99 & 2.67. Transgene Biotek has given -60.18% in this year & -9.33% in the last 5 days. The company posted a net profit of -0.39 Crores in its last quarter.Listed peers of Transgene Biotek include Sun Pharmaceutical Industries (-0.69%), Cipla (0.20%), Divi's Laboratories (-0.27%).The Mutual Fund holding in Transgene Biotek was at -% in . The MF holding has - from the last quarter. The FII holding in Transgene Biotek was at -% in . The FII holding has - from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Dec 13, 2025, 11:08 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    1.33
    High volatility
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    -
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
2.67
Highest
2.99
52 week range
Lowest
2.61
Highest
8.00
Transgene Biotek Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries
Bullish
1,794.50-0.694,30,478.6837.946.040.880.50
Cipla
Neutral
1,515.150.201,22,397.5523.333.940.850.81
Divi's Laboratories
Bullish
6,414.50-0.271,70,282.1778.2711.470.460.01
Torrent Pharmaceuticals
Bullish
3,780.00-0.561,27,870.0566.6416.920.8417.62
Dr Reddy's Laboratories
Bullish
1,279.500.511,06,784.7818.803.170.632.34
Transgene Biotek Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-11-14Quarterly Results
2025-08-07Quarterly Results
2025-05-07Audited Results
2025-01-24Quarterly Results
2024-11-12Quarterly Results & A.G.M.
About the company Transgene Biotek
  • IndustryBiotechnology & Drugs
  • ISININE773D01018
  • BSE Code526139
  • NSE Code
Transgene Biotek Limited is an India-based biotechnology company. It is engaged in the research and development of vaccines, oncology, and new drug delivery technologies. Its portfolio of products includes oncology, autoimmunity, drug delivery and biogenetics. The Company offers TrabiAAV, which is a platform for the delivery of micro-ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL drug is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203 drug is used to strengthen cell-mediated immunity and complete the elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus drug suppresses the immune system and is mainly used to prevent rejection of transplanted organs.
  • Management Info
  • K. Koteswara RaoManaging Director
Transgene Biotek Share Price FAQs

Transgene Biotek is trading at 2.99 as on Fri Dec 12 2025 09:58:58. This is 9.93% upper as compared to its previous closing price of 2.72.

The market capitalization of Transgene Biotek is 19.67 Cr as on Fri Dec 12 2025 09:58:58.

The 52 wk high for Transgene Biotek is 8.00 whereas the 52 wk low is 2.61

Transgene Biotek can be analyzed on the following key metrics -

  • TTM P/E:
  • Sector P/E: 2.08
  • Dividend Yield: 0.00%
  • D/E ratio: -

Transgene Biotek reported a net profit of -0.68 Cr in 2025.